Trial Watch: Immunostimulatory cytokines.

Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36

Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.22

Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology (2013) 1.21

Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17

Trial watch: DNA vaccines for cancer therapy. Oncoimmunology (2013) 1.11

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res (2014) 1.08

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics (2014) 1.02

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

Victories and deceptions in tumor immunology: Stimuvax(®) Oncoimmunology (2013) 0.91

Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother (2013) 0.87

Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model. PLoS One (2016) 0.84

Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology (2015) 0.84

Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. J Transl Med (2015) 0.83

Post-transcriptional regulation of cytokine signaling by AU-rich and GU-rich elements. J Interferon Cytokine Res (2014) 0.83

Cancer immunotherapy turns viral. Oncoimmunology (2013) 0.82

Cytokines reinstate NK cell-mediated cancer immunosurveillance. J Clin Invest (2014) 0.82

Immuno-modulatory Effect of IFN-gamma in AMD and its Role as a Possible Target for Therapy. J Clin Exp Ophthalmol (2013) 0.80

Novel insights into the mechanism of action of lenalidomide. Oncoimmunology (2014) 0.79

Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. Cancers (Basel) (2014) 0.79

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One (2015) 0.79

Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res (2015) 0.77

Rejuvenated T cells attack old tumors. Oncoimmunology (2013) 0.76

Association between IL-10 polymorphisms (-1082A/G, -592A/C and -819T/C) and oral cancer risk. Int J Clin Exp Med (2015) 0.75

Inflammation and cancer. Nature (2002) 53.78

An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42

Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57

Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature (1988) 13.42

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04

The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32

Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95

Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med (2007) 11.62

Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science (1994) 11.33

IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22

Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity (1995) 10.59

Role of transforming growth factor beta in human disease. N Engl J Med (2000) 10.17

Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ (2011) 9.44

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Viruses and interferon: a fight for supremacy. Nat Rev Immunol (2002) 7.92

IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature (2008) 7.00

TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol (2007) 6.34

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6.22

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med (2012) 6.01

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature (2000) 5.86

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev (2003) 5.57

Functional specialization of interleukin-17 family members. Immunity (2011) 5.36

An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med (2010) 4.95

Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature (1990) 4.46

Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43

The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE (2003) 4.14

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01

The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer (2003) 3.97

Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. 3. Analysis of mechanism. J Exp Med (1968) 3.88

Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 3.73

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol (2005) 3.73

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59

cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science (1988) 3.56

Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer (2011) 3.55

Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54

Targeting tyrosine kinases in cancer: the second wave. Science (2006) 3.52

Interleukin-10 therapy--review of a new approach. Pharmacol Rev (2003) 3.51

Biology of interleukin-10. Cytokine Growth Factor Rev (2010) 3.41

Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med (2002) 3.20

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12

Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med (2006) 3.09

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80

TRAIL and apoptosis induction by TNF-family death receptors. Oncogene (2003) 2.75

Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res (1982) 2.70

Interleukin-4 and interleukin-13 signaling connections maps. Science (2003) 2.69

The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature (1987) 2.68

PDGF receptors as cancer drug targets. Cancer Cell (2003) 2.66

Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest (1991) 2.66

Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity (2012) 2.57

2. Cytokines and chemokines. J Allergy Clin Immunol (2003) 2.54

Hematopoietic cytokines. Blood (2008) 2.45

Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell (2001) 2.45

Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol (2011) 2.25

CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science (1996) 2.21

Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov (2003) 2.18

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum (2008) 2.17

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood (2003) 2.16

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04

Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J (1997) 2.03

Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Natl Acad Sci U S A (1968) 1.95

Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88

Identification and characterization of a novel beta chemokine containing six conserved cysteines. J Immunol (1997) 1.87

Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 1.85

The many faces of Th17 cells. Curr Opin Immunol (2011) 1.84

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol (2009) 1.78

CD95, BIM and T cell homeostasis. Nat Rev Immunol (2009) 1.73

Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal (2010) 1.66

PDGF-D is a potent transforming and angiogenic growth factor. Oncogene (2003) 1.63

20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol (2011) 1.60

IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59

The interleukin-10 family of cytokines. Trends Immunol (2002) 1.54

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut (2006) 1.52

Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol (2002) 1.48

Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem (2001) 1.47

The colony-stimulating factors and cancer. Nat Rev Cancer (2010) 1.44

New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol (2011) 1.43

Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol (2006) 1.41

Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med (1997) 1.35

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2011) 1.32

Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci U S A (1995) 1.32

Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J (2011) 1.28

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res (2007) 1.26

SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol (2011) 1.25

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer (2011) 1.22

SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol (2004) 1.20

Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18

Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15

3. Cytokines and chemokines. J Allergy Clin Immunol (2006) 1.15

Selective release of a processed form of interleukin 1 alpha. Cytokine (1994) 1.11

Autophagy in the pathogenesis of disease. Cell (2008) 34.68

Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92

Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08

Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47

The hallmarks of aging. Cell (2013) 14.29

Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90

The pathophysiology of mitochondrial cell death. Science (2004) 13.87

Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79

Mitochondrial membrane permeabilization in cell death. Physiol Rev (2007) 12.72

Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72

Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54

Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27

Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06

Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73

Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20

Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13

Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99

Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97

Autophagy and aging. Cell (2011) 5.96

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62

Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23

Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00

Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91

Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75

Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48

Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30

Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07

The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01

The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci (2005) 3.93

Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91

Targeted deletion of AIF decreases mitochondrial oxidative phosphorylation and protects from obesity and diabetes. Cell (2007) 3.82

Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science (2011) 3.74

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41

Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol (2011) 3.41

Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol (2011) 3.40

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26

Does autophagy contribute to cell death? Autophagy (2005) 3.21

A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21

Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle (2006) 3.21

AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19

Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17

Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10

BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy (2007) 3.08

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89

Stimulation of autophagy by the p53 target gene Sestrin2. Cell Cycle (2009) 2.72

Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72

Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70

Platelet formation is the consequence of caspase activation within megakaryocytes. Blood (2002) 2.62

Necroptosis: a specialized pathway of programmed necrosis. Cell (2008) 2.61

Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med (2003) 2.56

Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res (2006) 2.56

Autophagy regulation by p53. Curr Opin Cell Biol (2010) 2.56

Can autophagy promote longevity? Nat Cell Biol (2010) 2.55

Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2009) 2.50